PHP14 ADDITION OF PHARMACY COST DATA IMPROVES PERFORMANCE OF THE ADJUSTED CLINICAL GROUPS PREDICTIVE MODEL FOR TOTAL HEALTH CARE COSTS OVERALL AND WITHIN DISEASE SPECIFIC GROUPS  by Powers, CA et al.
371Abstracts
product during the same visit. CONCLUSION: Expenditures for
OTC medications within the Texas Medicaid Pharmacy Program
accounted for 1.1% of total program payments. Clients under
the age of 18, especially infants, are the largest beneﬁciary group
of OTC medication coverage within the Texas Medicaid
Program.
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OBJECTIVE: To determine the effect of adding the pharmacy
cost data option to the Adjusted Clinical Groups Predictive
Model (ACG-PM) when estimating future total health care costs.
METHODS: Longitudinal analysis using medical and pharmacy
claims data from a large state employer over a 2-year period
(baseline May 1, 2001—April 30, 2002; follow-up May 1,
2002—April 30, 2003). Continuously eligible subjects <65 years
old at the end of the study period were selected. The total cost
Predictive Resource Index from the Johns Hopkins ACG System
Version 6.0 was used to predict inﬂation-adjusted follow-up year
total costs per member (medical plus pharmacy) using baseline
demographic and diagnosis information, with and without
including total pharmacy cost data. Results were compared to
actual follow-up year total costs by grouping actual and pre-
dicted costs ($0; $1–$1,000; $1,001–$5,000; $5,001–$10,000;
>$10,000) and comparing the positive predictive value (PPV)
within each cost grouping. Sensitivity and speciﬁcity were also
individually examined. Analyses were additionally conducted
within disease-speciﬁc subgroups, including diabetes, depression,
asthma, and cardiovascular disease. RESULTS: In the baseline
year, approximately 70% and 75% of the 344,834 included sub-
jects used medical and pharmacy services, respectively. Baseline
total cost averaged $2,665 (median: $621) and pharmacy cost
averaged $640 (median: $167). Follow-up mean actual total 
cost was $3193 (median: $748) and mean ACG-PM predicted
costs were $2789 from both models without and with 
pharmacy costs (respective medians: $1638; $1635). Including
pharmacy costs in the model increased the PPV, especially at
high-cost groups: 40.77% to 48.74% (+7.97%) at >$10,000 and
23.97% to 28.18% (+4.21%) at $5,001–$10,000. PPVs were
higher within disease-speciﬁc subgroups and increased with
inclusion of pharmacy costs, with the highest PPVs in the depres-
sion cohort (>10,000: 51.31% (without pharmacy costs) to
58.92% (with pharmacy costs); $5,000-$10,000: 29.92% to
35.31%). CONCLUSIONS: Addition of pharmacy cost data 
to the ACG-PM results in more accurate identiﬁcation of future
total health care costs, especially among high-cost members.
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OBJECTIVES: Washington Panel and UK NICE guidelines
propose that the health affects of patient care on their carers
should be included within the denominator of cost-utility analy-
ses. The impact of patient disability on carers has been demon-
strated by directly measuring the quality of life (QoL) of carers
in speciﬁc patient populations with substantial informal care
needs. However, it is possible that a general relationship between
patient and carer quality of life exists, whereby any improve-
ments in patient QoL are mirrored by improvements in carer
QoL. If such a general relationship does exist, any intervention
that generates additional patient quality adjusted life years
(QALYs) will also generate additional carer QALYs. We investi-
gated whether a general relationship between patient and carer
QoL exists using the Health Outcomes Data Repository
(HODaR). METHODS: Using a sample of 15,113 patients we
estimated the relationship between utility and time away from
normal activities for patients, along with the relationship
between patient utility and carer time spent helping patients. For
any given patient utility we can then predict carer time, and
assuming that this has the same impact on well-being as time
away form normal activities has on patients, predict carer utility.
RESULTS: A simple relationship shows that a reduction in utility
of 0.10 was associated with a 0.017 reduction in carer utility
(i.e. QALY gains are increased by 17%). More complex models
looked at the type of disabilities that were associated with greater
or lesser carer effects. CONCLUSION: This work is preliminary,
but points to the possibility of a general relationship between
patient and carer QoL. Additional research is required that
directly measures carer QoL, and identiﬁes whether it was inﬂu-
enced by the general health of the patient or speciﬁc disabilities.
Any widespread effect may have a profound effect on the future
funding decisions.
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OBJECTIVE: To study the effects of improvement in patients’
health on the welfare of their family members and its implica-
tions to medical cost-effectiveness analysis. METHODS: We use
a theoretical model based on a family utility function with altru-
istic linkages to show that there can be direct and indirect welfare
effects to all family members. Using the SEER-Medicare data-
base we test the predictions of our model by studying treatment
choice of prostate cancer patient by age and marital statuses.
RESULTS: The theoretical model suggests that a health inter-
vention has both the traditional direct effects on the patient, and
spillover effects on the family. In a 2-person household, the
spillover effect is ﬁrst the average change in QOL of the spouse
multiplied second by the probability that the patient remains
married at all future time periods. The magnitude and direction
of the ﬁrst component is based on a tradeoff between positive
spillover effects due to treatment related survival and QOL 
beneﬁts to the patient and negative spillover effects due to side
effects of treatment. Treatments for clinically localized prostate
cancer present such tradeoffs with positive spillover effects to the
spouse dominating for patients aged 60–70 years and vice versa
for older patients. Since the second component differs between
married and unmarried patients between these two age ranges,
we are able to test our theory by studying differences in treat-
ment choice between married and unmarried patients by age.
After controlling for clinical characteristics and patient demo-
graphics, we ﬁnd that the proportion of married patients 60–70
years of age who choose aggressive treatments for prostate
cancer is signiﬁcantly greater than the corresponding proportion
of unmarried patients. This pattern reverses at higher ages of the
patient. CONCLUSIONS: We conclude that cost-effectiveness
analyses may better reﬂect the full costs and beneﬁts of medical
interventions if they incorporate these family effects.
